Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Phase I study of PKC412 an Oral FLT3 Kinase Inhibitor, in Sequential and Concomitant Combinations with daunorubicin and cytarabine (DAA) Induction and High-Dose Cytarabine (HDAra-C) Consolidation in Newly Diagnosed Patients with AML

Phase I study of PKC412 an Oral FLT3 Kinase Inhibitor, in Sequential and Concomitant Combinations with daunorubicin and cytarabine (DAA) Induction and High-Dose Cytarabine (HDAra-C) Consolidation in Newly Diagnosed Patients with AML. Blood. 2004; 104:78a.


© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.